Pharsight

Ibrance is owned by Pfizer.

Ibrance contains Palbociclib.

Ibrance has a total of 6 drug patents out of which 3 drug patents have expired.

Expired drug patents of Ibrance are:

US7456168
US6936612
US7208489

Ibrance was authorised for market use on 03 February, 2015.

Ibrance is available in capsule;oral dosage forms.

Ibrance can be used as palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy.

The generics of Ibrance are possible to be released after 24 May, 2036.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6936612	PFIZER	2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones	Jan, 2023 (21 days ago)
US7208489	PFIZER	2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones	Jan, 2023 (21 days ago)
USRE47739	PFIZER	2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones	Mar, 2027 (4 years from now)
US10723730	PFIZER	Solid forms of a selective CDK4/6 inhibitor	Feb, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168	PFIZER	2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones	Jan, 2023 (21 days ago)
US11065250	PFIZER	Solid dosage forms of palbociclib	May, 2036 (13 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 03 February, 2015

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy

Dosage: CAPSULE;ORAL